The controversy surrounding Cassava Sciences and its experimental Alzheimer's drug, simufilam, has garnered significant attention within the medical and research communities, as well as among regulatory bodies and patient advocacy groups. Allegations of data manipulation and scientific
Biopharmaceutical companies face numerous challenges in the quest to develop and commercialize effective oncology drugs. The intricate journey from Phase 1 trials to market approval often sees only a small fraction of drugs succeeding, and even when they do, understanding how new drug approvals
Patient recruitment for clinical trials in the biopharma industry is often a challenging task. Successful recruitment strategies can significantly impact the efficiency and effectiveness of clinical trials, ultimately contributing to bringing new therapies to market faster. To achieve this,
Zephyrm Bioscience has announced its intention to pursue an initial public offering (IPO) on the Hong Kong stock exchange. The biotech company aims to secure significant funding to advance its lead cell therapy candidate, ZH901, into phase 3 clinical trials. ZH901 is targeted at treating both a
The world of medical and pharmaceutical advancements is frequently marked by innovative partnerships that push the boundaries of what is possible in patient care. One such collaboration has recently emerged between Excellos Inc. and Galapagos. These two entities have teamed up to enhance the
The biotech and pharmaceutical industries are highly dynamic fields reliant on constant innovation, robust networking, and strategic investor relations. Professionals in these sectors must attend top biopharma conferences to keep pace with the latest advancements, regulatory trends, and emerging
